Centene (NYSE:CNC) Issues FY 2026 Earnings Guidance

Centene (NYSE:CNC) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 4.800- for the period, compared to the consensus earnings per share estimate of 3.490. The company issued revenue guidance of $193.5 billion-$197.5 billion, compared to the consensus revenue estimate of $190.5 billion.

Analyst Upgrades and Downgrades

Several research firms have issued reports on CNC. Truist Financial increased their target price on Centene from $71.00 to $78.00 and gave the stock a “buy” rating in a research report on Tuesday, July 14th. JPMorgan Chase & Co. increased their price objective on Centene from $52.00 to $60.00 and gave the stock a “neutral” rating in a report on Monday, June 8th. Deutsche Bank Aktiengesellschaft upgraded Centene from a “hold” rating to a “buy” rating and raised their target price for the stock from $53.00 to $80.00 in a research note on Wednesday, May 20th. Jefferies Financial Group upped their price target on Centene from $39.00 to $48.00 and gave the company a “hold” rating in a research report on Wednesday, April 29th. Finally, Zacks Research lowered shares of Centene from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 29th. Seven research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Centene presently has an average rating of “Hold” and a consensus price target of $67.00.

Centene Price Performance

Shares of Centene stock opened at $60.85 on Thursday. The firm has a market capitalization of $30.05 billion, a PE ratio of -5.91, a price-to-earnings-growth ratio of 0.36 and a beta of 1.07. The company has a current ratio of 1.15, a quick ratio of 1.12 and a debt-to-equity ratio of 0.71. Centene has a 12 month low of $25.08 and a 12 month high of $69.36. The business’s 50-day moving average price is $63.74 and its 200-day moving average price is $50.09.

Centene (NYSE:CNC) last released its earnings results on Tuesday, July 28th. The company reported $2.51 earnings per share for the quarter, topping analysts’ consensus estimates of $1.09 by $1.42. The company had revenue of $53.58 billion during the quarter, compared to the consensus estimate of $47.64 billion. Centene had a positive return on equity of 12.12% and a negative net margin of 2.51%.Centene’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.16) EPS. Centene has set its FY 2026 guidance at 4.800- EPS. Sell-side analysts forecast that Centene will post 4.8 EPS for the current fiscal year.

Key Headlines Impacting Centene

Here are the key news stories impacting Centene this week:

• Positive Sentiment: Centene reported second-quarter adjusted earnings of $2.51 per share, well above the $1.09 analyst consensus, while revenue reached $53.58 billion versus expectations of $47.64 billion. Improved medical-cost trends, premium growth and stronger Marketplace performance supported the results. Centene Q2 Earnings Beat Estimates on Increasing Premiums
• Positive Sentiment: The insurer raised its 2026 earnings outlook to approximately $4.80 per share, citing better cost control, margin recovery and improved performance across its Medicare, Medicaid and Marketplace businesses. Centene Stock Q2 Earnings Call Highlights Margin Recovery
• Positive Sentiment: Analysts continue to see potential upside following the earnings recovery. Robert W. Baird raised its price target to $66 from $46, although it maintained a Neutral rating. Benzinga analyst price target report
• Neutral Sentiment: Centene announced the partial redemption of $500 million of its 4.25% 2027 notes, a balance-sheet and capital-management action that could modestly reduce future interest expense. Centene Announces Partial Redemption of 2027 Notes
• Negative Sentiment: Medicaid membership declined, and investors remain concerned about the sustainability of earnings as enrollment reductions and Medicaid-related policy and utilization pressures weigh on the business. Those concerns appear to be overshadowing the quarterly beat and guidance increase. Oscar Health Flashes Buy Signal As Medicaid Weighs On Centene
• Negative Sentiment: The stock’s sharp prior rally has also left valuation and expectations elevated, making it more vulnerable to profit-taking when investors focus on membership declines rather than near-term margin improvement. Centene Stock Still Looks Like a Bargain As Its Run Continues

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. DV Equities LLC purchased a new stake in Centene during the 4th quarter valued at about $26,000. IFC & Insurance Marketing Inc. bought a new stake in Centene in the fourth quarter valued at approximately $28,000. McMillan Office Inc. purchased a new stake in shares of Centene during the fourth quarter valued at approximately $49,000. MUFG Securities EMEA plc bought a new position in shares of Centene in the second quarter worth approximately $79,000. Finally, Intesa Sanpaolo Wealth Management bought a new stake in Centene during the 4th quarter valued at $60,000. Hedge funds and other institutional investors own 93.63% of the company’s stock.

About Centene

Centene Corporation (NYSE: CNC) is a diversified, multi-national healthcare enterprise that specializes in providing services to government-sponsored and national health programs. The company primarily acts as a managed care organization, delivering healthcare coverage and administering benefits for Medicaid, the Children’s Health Insurance Program (CHIP), Medicare Advantage, and individual marketplace plans. Centene also contracts with federal and state agencies to manage specialty care programs and community-based services for vulnerable populations.

Centene’s offerings extend beyond traditional insurance to include a range of specialty and support services.